Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 19/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 19/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 19/20 | 1.00 |
| ▸ | GCGR | P47871 | 12/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 4/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.88 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.88 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.88 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.88 |
| ▸ | FRK | P42685 | 2/20 | 0.88 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.88 |
| ▸ | GSK3B | P49841 | 2/20 | 0.88 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.88 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.88 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.88 |
| ▸ | RAF1 | P04049 | 7/20 | 0.83 |
| ▸ | BRAF | P15056 | 2/20 | 0.77 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9195042 | 1.00 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL19868948 | 0.99 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL19868925 | 0.94 | MAPK11 (1.00) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL15075603 | 0.94 | MAPK11 (1.00) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL16292225 | 0.92 | MAPK13 (0.85) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL1629037 | 0.92 | MAPK13 (0.85) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL2949385 | 0.91 | MAPK13 (1.00) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL7228717 | 0.91 | MAPK13 (1.00) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL2650007 | 0.90 | MAPK14 (0.81) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL2650702 | 0.88 | MAPK11 (1.00) | MAPK14MAPK13MAPK12MAPK11GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6288089-B1 | ADMINISTERING A COMPOSITION OF PYRIDYL IMIDAZOLE COMPOUNDS TO TREAT PARKINSON'S DISEASE, HUNTINGTON'S DISEASE, ALZHEIMER'S DISEASE, AND AMYOTOPHIC LATERAL SCLEROSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-09-11 | — | — | US | claimed |
| CN-1083473-A | New imidazolium compounds and pharmaceutical composition thereof | SMITHKLINE BEECHAM CORP (US) | 1994-03-09 | — | — | CN | claimed |
| US-10865384-B2 | 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-12-15 | — | — | US | disclosed |
| US-20180044316-A1 | POTENTIATORS OF BETA-LACTAM ANTIBIOTICS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2018-02-15 | — | — | US | disclosed |
| US-20170166867-A1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-06-15 | — | — | US | disclosed |
| US-20170166867-A1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-06-15 | — | — | US | disclosed |
| WO-2015119579-A1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-08-13 | — | — | WO | disclosed |
| EP-1487436-A4 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | SIGNAL PHARM INC (US) | 2009-06-03 | — | — | EP | disclosed |
| US-7351729-B2 | JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070149571-A1 | Combination therapy for treating or managing acute myelocytic leukemia | SIGNAL PHARMACEUTICALS, LLC | 2007-06-28 | — | — | US | disclosed |
| EP-1487436-A1 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | Signal Pharmaceuticals, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20030064997-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-03 | — | — | US | disclosed |
| US-6288089-B1 | ADMINISTERING A COMPOSITION OF PYRIDYL IMIDAZOLE COMPOUNDS TO TREAT PARKINSON'S DISEASE, HUNTINGTON'S DISEASE, ALZHEIMER'S DISEASE, AND AMYOTOPHIC LATERAL SCLEROSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-09-11 | — | — | US | disclosed |
| US-6268370-B1 | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-07-31 | — | — | US | disclosed |
| US-6235760-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS | SMITHKLINE BEECHAM CORPORATION | 2001-05-22 | — | — | US | disclosed |
| US-5916891-A | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-29 | — | — | US | disclosed |
| US-5686455-A | Imidazole derivatives and their use as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1997-11-11 | — | — | US | disclosed |
| US-5656644-A | CYTOKINE SUPPRESSORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| EP-0623126-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014081-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149571-A1 | Combination therapy for treating or managing acute myelocytic leukemia | MCL1, ATF1, MAP3K5 | MAPK14 69/4885MAPK13 66/4885MAPK12 59/4885 |
| US-10865384-B2 | 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis | CSNK1A1, CSNK1G1, CSNK2A1 | MAPK14 241/4885MAPK13 234/4885MAPK12 366/4885 |
| US-20030064997-A1 | Novel compounds | BRD4, BRDT, HDAC6 | MAPK14 3769/4885MAPK13 2219/4885MAPK12 3250/4885 |
| US-20180044316-A1 | POTENTIATORS OF BETA-LACTAM ANTIBIOTICS | CREB1, PPP6R1, PPP1R10 | MAPK14 440/4885MAPK13 782/4885MAPK12 363/4885 |
| US-20170166867-A1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | CSNK1A1, CSNK1G1, CSNK2A1 | MAPK14 241/4885MAPK13 234/4885MAPK12 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.